Poseida Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company. The Company provides differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing.

Employees

350

Sector

Biotechnology & Medical Research

More about the company

Market Closed - Nasdaq 16:00:00 2025-01-07 EST			5-day change	1st Jan Change
9.500 ^USD	-0.63%		-.--%	-

25-01-09	Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from S&P TMI Index	CI
25-01-08	Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from NASDAQ Composite Index	CI

Market Cap	939M 804M 752M 689M 1.29B 89.81B 1.31B 8.89B 3.47B 45.11B 3.52B 3.45B 149B	P/E 2022	-5.96x	P/E 2023	-2.45x
Enterprise Value	812M 695M 651M 596M 1.12B 77.68B 1.13B 7.69B 3B 39.02B 3.05B 2.98B 129B	EV / Sales 2022	2,006,182x	EV / Sales 2023	3,006,338x
Free-Float	72.36%	Yield 2022 *	-	Yield 2023	-

25-01-09	Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from S&P TMI Index	CI
25-01-08	Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from NASDAQ Composite Index	CI
25-01-08	Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from S&P Global BMI Index	CI
25-01-08	Swiss Market Index Extends Winning Streak; Partners Group Gains	MT
25-01-08	Poseida Therapeutics Acquisition Set to Be Completed, Roche Says	MT
25-01-08	Roche: Poseida acquisition nears completion
25-01-08	Roche to Complete Takeover of Poseida Therapeutics After Tender Offer Closes	MT
25-01-08	Roche to complete acquisition of U.S. biopharma company Poseida	RE
25-01-06	Roche Holdings, Inc. completed the acquisition of Poseida Therapeutics, Inc. from Malin Corporation PLC, Pentwater Capital Management and others.	CI
24-12-11	Poseida Therapeutics Insider Sold Shares Worth $283,866, According to a Recent SEC Filing	MT
24-12-10	Roche: launch of takeover bid for Poseida Therapeutics
24-12-09	Roche Launches Tender Offer for Poseida Therapeutics	MT
24-12-09	Poseida Therapeutics Says New Data Support Potential of Allogeneic Cell Therapy Platform	MT

24-12-02	Piper Sandler Downgrades Poseida Therapeutics to Neutral, $10 Price Target	MT
24-11-26	Cantor Fitzgerald Downgrades Poseida Therapeutics to Neutral From Overweight	MT
24-11-26	BTIG Downgrades Poseida Therapeutics to Neutral	MT
23-12-11	Piper Sandler Adjusts Price Target on Poseida Therapeutics to $10 From $8, Maintains Overweight Rating	MT
23-12-11	HC Wainwright Adjusts Price Target on Poseida Therapeutics to $20 From $15, Keeps Buy Rating	MT

Poseida Therapeutics, Inc. Stock

Stocks

PSTX

US73730P1084

Biotechnology & Medical Research

Valuation: Poseida Therapeutics, Inc.

Latest news : Poseida Therapeutics, Inc.

Analysts' recommendations: Poseida Therapeutics, Inc.

Press Releases: Poseida Therapeutics, Inc.

News in other languages: Poseida Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Poseida Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

24-11-27	POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX	BU
24-11-27	Poseida Therapeutics, Inc. Announces Agreement to be acquired by Roche Holdings, Inc.	AQ
24-11-26	Poseida Therapeutics : Announces Agreement to be Acquired by Roche Holdings, Inc Form 8 K	PU
24-11-14	Poseida Therapeutics : Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline Form 8 K	PU
24-11-14	Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline	PR

25-01-08	Roche : l'acquisition de Poseida en passe d'être finalisée
25-01-08	Roche reprend la majorité de Poseida Therapeutics
25-01-08	Roche steht kurz vor Abschluss der Poseida-Übernahme
24-12-10	En Direct des Marchés : Vivendi fait des petits, Euroapi change tout, Oracle voit trouble
24-12-10	Wall Street vacille, l'Europe s'éparpille, la Chine scintille

Manager	Title	Age	Since
Dara Pincas CEO	Chief Executive Officer	-	-
Johanna Mylet DFI	Director of Finance/CFO	39	2020-06-30
Syed Rizvi CTO	Chief Tech/Sci/R&D Officer	59	2024-03-31

Director	Title	Age	Since
Sean Johnston BRD	Director/Board Member	-	2025-01-07
Roger Brown BRD	Director/Board Member	-	2025-01-07

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/8/25	Charles Baum	Tender	Director	190,300	0.1952%
1/8/25	Rafael Amado	Tender	Director	141,500	0.1452%
1/8/25	MALIN CORP. PLC	Tender	Company	11,835,673	12.1435%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
POSEIDA THERAPEUTICS, INC.	-0.63%	-.--%	-.--%	+297.49%	929M
WUXI APPTEC CO., LTD.	-3.00%	+2.27%	+77.60%	+109.33%	73.96B
ARGENX SE	+1.90%	+23.53%	+56.60%	+97.76%	64.66B
BIONTECH SE	+5.12%	+25.22%	+5.24%	-0.82%	27.86B
INSMED INCORPORATED	+0.55%	+1.64%	-5.15%	+471.68%	27.32B
WUXI BIOLOGICS (CAYMAN) INC.	+2.74%	+12.98%	+62.84%	+28.14%	25.97B
GENMAB A/S	+0.47%	+6.12%	+36.66%	-13.79%	19.98B
PHARMAESSENTIA CORPORATION	+1.82%	-6.67%	+247.46%	+393.10%	17.84B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.94%	+3.36%	+18.55%	+532.94%	16.24B
EXELIXIS, INC.	+0.73%	+5.54%	+39.71%	+153.07%	13.3B
Average	+1.06%	+6.85%	+53.95%	+206.89%	28.81B
Weighted average by Cap.	+0.68%	+8.72%	+59.06%	+158.67%

	2022	2023
Net sales	130.49 111.78 104.59 95.74 179.68 12.49K 182.05 1.24K 481.88 6.27K 489.98 479.32 20.75K	64.7 55.42 51.86 47.47 89.09 6.19K 90.27 612.7 238.94 3.11K 242.95 237.67 10.29K
Net income	-64M -54.82M -51.3M -46.96M -88.12M -6.12B -89.29M -606M -236M -3.08B -240M -235M -10.17B	-123M -106M -98.93M -90.56M -170M -11.81B -172M -1.17B -456M -5.93B -463M -453M -19.62B
Net Debt	-194M -166M -155M -142M -267M -18.54B -270M -1.83B -715M -9.31B -727M -712M -30.8B	-127M -109M -102M -93.02M -175M -12.13B -177M -1.2B -468M -6.09B -476M -466M -20.15B

3 years	1.83	9.67
5 years	1.54	11.1
10 years	1.54	17.62